Prostaglandin D2 (PGD2) is an acidic lipid mediator that is derived from arachidonic acid by the sequential action of cyclooxygenase(s) (COX) and PGD2 synthase(s). Arachidonic acid is converted by COX-1 and COX-2 in a two-step process to first PGG2 and then PGH2. These unstable endoperoxide intermediates are converted to PGD2 by either the haematopoietic or lipocalin PGD2 synthase. PGD2 is produced in the brain where it might be involved in the regulation of sleep and other central nervous system (CNS) activities, including pain perception. In peripheral tissues, the richest cellular source of PGD2 is the mast cell[1]. The CRTH2 receptor is an important mediator of the inflammatory effects of PGD2. Strikingly, as a member of the subfamily of GPCR-A14, it has low homology to the rest of the prostaglandin receptors, but high sequence homology to chemoattractant receptors such as the N-formyl peptide receptors and cysteinyl leukotriene receptors. The receptor is expressed on TH2 cells, but not on TH1 cells, and hence the name chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2)[2].

Prostanoid receptor subtypes listed: CRTH2, PGD2 (DP1), PGE2 (EP1)PGE2 (EP2)PGE2 (EP3), Thromboxane A2

[1] R. Pettipher et al. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug Discov. 2007, 6, 313-325.
[2] T. Ulven et al. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin. Ther. Pat. 2010, 20, 1505-1530.

3 Item(s)

per page
Axon ID Name Description From price
2145 AZD1981 Selective CRTH2 (aka DP2) antagonist €90.00
1913 Timapiprant Selective DP2 (CRTH2) antagonist €90.00
3966 TM30089 sodium Selective CRTH2 antagonist Inquire

3 Item(s)

per page
Please wait...